The following represents disclosure information provided by authors of this abstract. The Breast Cancer Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Hormone receptor positive (HR+)/human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer: Sequencing of chemotherapy and endocrine therapy.
Nicole M. Engel-Nitz
Research Funding - Novartis
Yanni Hao
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Jaqueline Willemann Rogerio
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
James D. Turnbull
Employment or Leadership Position - Novartis
Gabriel Gomez Rey
Research Funding - Novartis
Jane Sullivan
Research Funding - Novartis
Arthur H. Rossof
Employment or Leadership Position - UnitedHealth Group
Stock Ownership - UnitedHealth Group